{
    "id": 28867,
    "fullName": "PLEKHA7 - ALK",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PLEKHA7-ALK results from the fusion of PLEKHA7 and ALK (PMID: 29883838). PLEKHA7-ALK has been identified in non-small cell lung cancer (PMID: 29883838) and renal cell carcinoma (PMID: 31993771), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Mar 2020).",
            "references": [
                {
                    "id": 18433,
                    "pubMedId": 31993771,
                    "title": "ALK-rearranged renal cell carcinoma with a novel PLEKHA7-ALK translocation and metanephric adenoma-like morphology.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31993771"
                },
                {
                    "id": 12672,
                    "pubMedId": 29883838,
                    "title": "Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29883838"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 144100,
        "geneSymbol": "PLEKHA7",
        "terms": [
            "PLEKHA7"
        ]
    },
    "variant": "PLEKHA7 - ALK",
    "createDate": "10/25/2018",
    "updateDate": "03/25/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 238,
                "geneSymbol": "ALK",
                "terms": [
                    "ALK",
                    "CD246",
                    "NBLST3"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15123,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, PLEKHA7-ALK was identified as an acquired resistance mutation in a patient with non-small cell lung cancer harboring EGFR L858R, whose disease progressed after initial response to Tarceva (erlotinib), followed by Gilotrif (afatinib), and Tagrisso (osimertinib) (PMID: 29883838).",
            "molecularProfile": {
                "id": 30768,
                "profileName": "PLEKHA7 - ALK EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12672,
                    "pubMedId": 29883838,
                    "title": "Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29883838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15137,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with lung adenocarcinoma harboring EGFR L858R and an acquired resistance mutation PLEKHA7-ALK demonstrated partial response of 6 months on Alecensa (alectinib) in combination with Tagrisso (osimertinib), whose disease progressed after 10 months of partial response with Tagrisso (osimertinib) alone (PMID: 29883838).",
            "molecularProfile": {
                "id": 30768,
                "profileName": "PLEKHA7 - ALK EGFR L858R"
            },
            "therapy": {
                "id": 7417,
                "therapyName": "Alectinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12672,
                    "pubMedId": 29883838,
                    "title": "Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29883838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30756,
            "profileName": "PLEKHA7 - ALK",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30768,
            "profileName": "PLEKHA7 - ALK EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}